Given that cancer immunotherapy drugs work better if tumors are infiltrated by CD8+ T cells, deeper analyses of the microenvironment of these tumors promise discovery of additional features of good prognosis and increased response to checkpoint blockade. This evidence concerns the gene CD8A and cancer.